증상성 신경성 기립성 저혈압(nOH) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Symptomatic Neurogenic Orthostatic Hypotension (nOH) Emerging Therapy and TPP Insights

Thelansis's "Symptomatic Neurogenic Orthostatic Hypotension (nOH) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Symptomatic Neurogenic Orthostatic Hypotension (nOH) Overview

Symptomatic neurogenic orthostatic hypotension (nOH) is a debilitating disorder of blood pressure regulation caused by impaired sympathetic release of norepinephrine upon standing. It arises from neurodegenerative alpha-synucleinopathies like Parkinson's disease and multiple system atrophy, or peripheral neuropathies. Pathophysiology involves the failure of baroreflex-mediated vasoconstriction, producing a sustained postural drop in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within three minutes of standing. It is differentiated from non-neurogenic orthostatic hypotension by a blunted compensatory heart rate increase of less than 15 beats per minute. Symptoms include standing lightheadedness, presyncope, and cognitive fog, which drive severe fall risks. Diagnosis combines orthostatic vitals, tilt-table testing, and plasma catecholamine assays. Non-pharmacological measures like compression garments and salt/fluid loading are foundational. Pharmacotherapy utilizes midodrine and droxidopa, supplemented by fludrocortisone. In 2026, protocols actively incorporate pyridostigmine or atomoxetine to optimize upright pressure without exacerbating supine hypertension, a frequent nocturnal complication requiring careful clinical balance.

Key Highlights

• In France, moderate-to-severe SnOH cases are projected to increase from 11.0K in 2025 to 11.2K by 2035, reflecting minimal growth (0.2% CAGR) and a relatively stable patient population.
• Persistent symptoms and incomplete response to existing therapies highlight a continued unmet need for more effective and durable treatment options.
• Increasing awareness and improved diagnosis, particularly in aging populations and neurodegenerative conditions, are expected to support gradual patient identification.

Market Overview

• The Germany SnOH market is projected to grow from $9M in 2025 to $11M by 2035, reflecting modest growth in line with a small and stable patient population.
• Limited market expansion is primarily driven by:
• Incremental uptake of existing therapies (e.g., midodrine, droxidopa)
• Gradual improvements in diagnosis and treatment rates
• The market remains constrained by low disease awareness, underdiagnosis, and limited innovation in therapeutic options.
• Future growth will depend on improved disease recognition and the development of more effective therapies addressing both symptomatic control and underlying autonomic dysfunction.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• CuraSen Therapeutics
• Theravance Biopharma

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)